One study demonstrated that salidroside ameliorated NASH by modulating the gut microbiota, which rectified BA metabolism by decreasing colonic toxic/conjugated BAs (such as DCA, TCA and tauro-α/β-muricholic acid (Tα/β-MCA)) and increasing β-CDCA, ultimately activating the hepatic and ileal FXR signaling axis, as well as the ileal FGF15 signaling axis (Li et al., 2020c). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.